Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
320.42
+1.51 (0.47%)
At close: Mar 17, 2026, 4:00 PM EDT
320.42
0.00 (0.00%)
After-hours: Mar 17, 2026, 4:15 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 28 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $467.68, which forecasts a 45.96% increase in the stock price over the next year. The lowest target is $330 and the highest is $583.
Price Target: $467.68 (+45.96%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 13 | 12 | 13 | 13 |
| Buy | 11 | 10 | 10 | 10 | 10 | 10 |
| Hold | 3 | 4 | 5 | 5 | 5 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 27 | 28 | 27 | 28 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $522 → $330 | Strong Buy → Hold | Downgrades | $522 → $330 | +2.99% | Mar 16, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $510 | Strong Buy | Reiterates | $510 | +59.17% | Feb 18, 2026 |
| Freedom Capital Markets | Freedom Capital Markets | Hold → Strong Buy Upgrades $470 → $410 | Hold → Strong Buy | Upgrades | $470 → $410 | +27.96% | Feb 17, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $415 → $429 | Strong Buy | Maintains | $415 → $429 | +33.89% | Feb 17, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $475 → $425 | Strong Buy | Maintains | $475 → $425 | +32.64% | Feb 13, 2026 |
Financial Forecast
Revenue This Year
5.67B
from 3.71B
Increased by 52.78%
Revenue Next Year
7.48B
from 5.67B
Increased by 31.86%
EPS This Year
7.46
from 2.33
Increased by 220.23%
EPS Next Year
11.16
from 7.46
Increased by 49.58%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.2B | 8.6B | |||
| Avg | 5.7B | 7.5B | |||
| Low | 5.1B | 6.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 67.3% | 51.3% | |||
| Avg | 52.8% | 31.9% | |||
| Low | 37.4% | 15.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 10.77 | 15.74 | |||
| Avg | 7.46 | 11.16 | |||
| Low | 4.79 | 7.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 362.4% | 110.9% | |||
| Avg | 220.2% | 49.6% | |||
| Low | 105.7% | 1.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.